Industry News
Many Women Not Receiving Recommended Breast Cancer Adjuvant Treatment
Dec 08, 2011
A first-of-its kind study led by Xiao-Cheng Wu, MD, MPH, Associate Professor of Public Health at LSU Health Sciences Center New Orleans, reports that a significant number of women are not receiving guideline-recommended treatment for breast cancer and what factors contribute. The research is published online in the Journal of Clinical Oncology... Read More
Identifying Interventions To Delay Or Prevent Breast Cancer Recurrences After Tamoxifen
Dec 08, 2011
An international research team led by Georgetown Lombardi Comprehensive Cancer Center has found biological differences in hormone-receptor positive breast cancer that are linked to the timing of recurrence despite endocrine therapy... Read More
Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events
Dec 08, 2011
A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence of distant metastases in postmenopausal women... Read More
After Partial Breast Irradiation, Side Effects, Complications, Mastectomy More Likely
Dec 08, 2011
Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), accor... Read More
Computer Aided Design Advances Breast Reconstruction
Dec 08, 2011
Breast reconstruction surgery will become both safer and more realistic thanks to research led by Queensland University of Technology (QUT). Professor Dietmar W... Read More
In Early Vs. Late Hormone Receptor-Positive Breast Cancer, Molecular Differences May Be Used To Predict Breast Cancer Recurrence
Dec 08, 2011
Researchers may have discovered a series of genes that will help predict whether or not a woman with hormone receptor-positive invasive breast cancer will experience early, late or no recurrence of her disease. Minetta C. Liu, M.D... Read More
Predicting Risk For Recurrence For Patients With DCIS Breast Cancer
Dec 08, 2011
In a significant advance for patients with ductal carcinoma in situ, researchers have developed and prospectively validated a multigene test to identify the risk for recurrence of breast cancer... Read More
Anemia In Dialysis Patients - Peginesatide Gets Green Light From FDA Advisory Panel
Dec 08, 2011
An FDA Advisory Committee has voted in favour of approving peginesatide for use with dialysis patients who developed anemia caused by CKD (chronic kidney disease). The Oncologic Drugs Advisory Committee (ODAC) voted 15 in favor, 1 against, with 1 abstention. Peginesatide is an ESA (synthetic erythropoiesis-stimulating agent)... Read More
Predicting Who Might Benefit From Additional Gastrointestinal Cancer Treatment - New Predictive Tool
Dec 07, 2011
According to a study published Online First in The Lancet Oncology, a new tool that can assess a person's risk of gastrointestinal stromal tumors recurrence after surgery is an important addition to current predictive models that will also help with the development of more accurate selection of high-risk patients who are most likely to benefit from additional treatment... Read More
Triple Drug Combo Eradicates 50% More Tumors In HER2-Positive Breast Cancer Than Standard Treatment
Dec 07, 2011
Findings of the phase 2 NeoSphere study, published Online First in The Lancet Oncology shows that by adding monoclonal antibody pertuzumab to standard therapy (trastuzumab [Herceptin] plus the chemotherapy drug docetaxel) for women with an aggressive type of early-stage breast cancer (HER2-positive disease) improved the rate of complete tumor disappearance by over half after just four cycles, i.e... Read More
Previous Page Next Page